Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Grammidin with Anesthetic Spray vs Lozenges in Healthy Volunteers
NCT06857890Phase 1Recruiting
- Sponsor
- Valenta Pharm
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gramicidin C + cetylpyridinium chloride in pharyngitis (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
gramicidin C + cetylpyridinium chloride
03
Conditions
pharyngitis
Beyond the preview
Go deeper on NCT06857890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857890.